256 related articles for article (PubMed ID: 17256133)
1. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Brem S; Tyler B; Li K; Pradilla G; Legnani F; Caplan J; Brem H
Cancer Chemother Pharmacol; 2007 Oct; 60(5):643-50. PubMed ID: 17256133
[TBL] [Abstract][Full Text] [Related]
2. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
3. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Vellimana AK; Recinos VR; Hwang L; Fowers KD; Li KW; Zhang Y; Okonma S; Eberhart CG; Brem H; Tyler BM
J Neurooncol; 2013 Feb; 111(3):229-36. PubMed ID: 23224713
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Wicks RT; Azadi J; Mangraviti A; Zhang I; Hwang L; Joshi A; Bow H; Hutt-Cabezas M; Martin KL; Rudek MA; Zhao M; Brem H; Tyler BM
Neuro Oncol; 2015 Jan; 17(1):70-80. PubMed ID: 25053853
[TBL] [Abstract][Full Text] [Related]
5. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Grossman R; Tyler B; Hwang L; Zadnik P; Lal B; Javaherian K; Brem H
J Neurosurg; 2011 Dec; 115(6):1139-46. PubMed ID: 21923243
[TBL] [Abstract][Full Text] [Related]
6. Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Serra R; Mangraviti A; Gorelick NL; Shapira-Furman T; Alomari S; Cecia A; Darjee N; Brem H; Rottenberg Y; Domb AJ; Tyler B
Eur J Pharm Biopharm; 2022 Jan; 170():179-186. PubMed ID: 34968646
[TBL] [Abstract][Full Text] [Related]
7. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Bow H; Hwang LS; Schildhaus N; Xing J; Murray L; Salditch Q; Ye X; Zhang Y; Weingart J; Brem H; Tyler B
J Neurosurg; 2014 Mar; 120(3):662-9. PubMed ID: 24359008
[TBL] [Abstract][Full Text] [Related]
8. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
Yuan X; Tabassi K; Williams JA
Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
[TBL] [Abstract][Full Text] [Related]
9. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Akbar U; Jones T; Winestone J; Michael M; Shukla A; Sun Y; Duntsch C
J Neurooncol; 2009 Sep; 94(2):203-12. PubMed ID: 19337695
[TBL] [Abstract][Full Text] [Related]
10. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with temozolomide in malignant glioma.
Mannas JP; Lightner DD; Defrates SR; Pittman T; Villano JL
J Clin Neurosci; 2014 Jan; 21(1):121-3. PubMed ID: 24063865
[TBL] [Abstract][Full Text] [Related]
14. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
15. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
17. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
19. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
Recinos VR; Bekelis K; Ziegler SG; Vick D; Hertig S; Tyler BM; Li KW; Kosztowski T; Legnani FG; Brem H; Olivi A
J Neurooncol; 2010 Mar; 97(1):1-10. PubMed ID: 19693439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
